Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot leg training tuned to each child may build stronger knees in SMA

NCT ID NCT07822711

Symptom relief Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing a portable knee-training robot in children aged 6 to 12 with spinal muscular atrophy. Each child trains one leg with a flexible, individually tuned stiffness setting and the other leg with a rigid setting for up to 8 weeks. The trial compares how much knee-extension strength changes in each leg, along with range of motion, muscle size on MRI, nerve function, and sit-to-stand ability. The goal is to see whether matching the robot's stiffness to each child helps build quadriceps strength better than a fixed rigid setting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A portable isokinetic knee training robot with an individually optimized compliant stiffness setting
What this could lead to
If the compliant setting helps more, it could shape how clinicians use robot-assisted leg training to slow muscle weakness in children with SMA.
What could go wrong
The trial is small, with about 13 children, and lasts up to 8 weeks, so any strength gains may be modest or fade. Children with SMA can tire easily, and training may cause knee pain or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 13 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 6 to 12 years. 2. Diagnosis of spinal muscular atrophy. 3. Able to maintain an independent seated position. 4. If receiving disease-modifying treatment, including nusinersen or risdiplam, the participant must have received a stable dose for at least 6 months before enrollment and must not change the treatment regimen during the study. Exclusion Criteria: 1. Any other major disease or medical condition that, in the investigator's judgment, would interfere with safe participation or interpretation of the study results. 2. The legal guardian declines to provide written informed consent, or the participant is unable to complete the study procedures. 3. Unable to undergo magnetic resonance imaging or electromyography and nerve conduction testing. 4. Blood pressure above the 95th percentile for age, sex, and height, as assessed by a clinician. 5. Lacks the cognitive capacity to understand or comply with the requirements of study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal muscular atrophy (SMA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

spinal muscular atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal muscular atrophy (SMA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University Third Hospital

    Beijing, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.